Next Phase Newsletter

A corporate venture arm is seeking to make investments in companies with an intersection of AI in various verticals such as manufacturing, automotive, healthcare and sustainability. The firm also makes investments in core technology enablers of AI. The firm has $300M AUM. Check size ranges from $1-10M but typically falls in the $3-5M range and the firm prefers equity investments. The firm has made three investments in companies with applications of AI in healthcare. The firm typically invest in Series A and B but will look at Pre Series A companies that are getting close to the Series A round. The firm is open to global opportunities.

The firm seeks to make investments relating to AI. The firm will look at therapeutics, medical devices, digital health and diagnostics as long as it is AI enabled. The firm is agnostic to subsector and indication. The firm does not look at pre-clinical and pre-prototype companies, but will look at earlier companies that are preparing for clinical trials on a case by case basis. The firm will invest in all three classes of medical devices.

The firm looks for management teams with a good network, and a diverse founding team is of particular interest. In healthcare investments, the firm typically co-invests, and will seek a board observer seat.
 
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm with offices in USA, Canada, and Europe, is investing from its latest fund which closed in early 2021. The firm makes seed, early-stage, and growth equity investments in biotechnology and medical devices companies, and with the latest fund they seek to invest in 20 or more biotech startups. The firm’s typical investment size for early-stage companies is between $5M to $15M. The firm can allocate up to $20M total over the life of the investment.  The firm focuses on companies that are based in the US, Canada, and Western Europe, but also selectively invests in companies in Asia. The firm is actively seeking new investment opportunities.

The firm is opportunistic in terms of subsectors and indications. The firm is interested in novel small molecule and biologic therapeutics that address immuno-oncology, orphan/rare or genetic-based diseases, inflammation, infectious diseases and specific viruses, microbiome, and fibrosis and CNS indications. The firm is also interested in regenerative medicine and gene therapy. In medical devices, the firm is generally agnostic to subsector, but is more interested in revenue-generating devices that address cardiovascular, orthopedic, ophthalmic and neurological disorders. The firm prefers devices with proof-of-concept and strong IP.

The firm seeks a company with a strong and experienced management team or technical experts in the relevant technology. The firm generally is flexible with management teams.
 
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in the USA with a presence in China, has great experience with working with regulatory agencies to gain product approval for both FDA and CFDA. The firm seeks to invest in 8-10 companies per year. The firm usually participates in seed to series B financing rounds with check sizes between $500K – 2M and will consider companies globally, with a focus on those in USA, Europe, and China.

The firm is opportunistic and will consider all early-stage opportunities in therapeutics, medical devices, diagnostics, and digital health, as long as the technology is considered highly disruptive. The firm’s greatest focus lies in the medical device sector in which the firm has the strongest expertise. In therapeutics, the firm will consider pre-clinical and phase I assets. In medical devices and diagnostics, the firm is open to all classes of medical devices including 510k and PMA that are in development or clinical trials. The firm has reviewed companies of various stages in the past: those that have just developed a valid prototype, and those that were already profitable prior to investment.

The firm seeks to work with companies with an experienced management team, ideally led by a serial entrepreneur with a successful track record. The firm can both lead and co-invest but prefers to lead financing rounds for medical device companies and will most likely take a board seat.
 
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A firm is focused on early stage investment to support founders and their teams advance healthcare solutions.  The team originated at a global medical device company that has worked with researchers and physicians for more than 50 years to develop more effective therapeutic tools. The firm participates in pre-seed, seed and A rounds as a dedicated partner working closely with startups to advance technologies and build companies. Initial investment ranges from $250k-$1M. The firm has a global presence and is open to early-stage companies from around the world.

The firm’s investment focus is on 1) digital solutions to improving healthcare and 2) the development of life science tools to enable the production of advanced therapeutics.

The firm has no strict requirements for companies or management teams.
 
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A multi-billion AUM firm based in the USA is known for investing in technologies that change paradigms. The firm is currently investing out of a $1 billion venture fund for later stage investments and a $400 million for seed-stage investments. The firm has invested across a multitude of industries, including healthcare. Within healthcare, the firm is agnostic, choosing to select companies based on their potential impact. The firm will invest globally and generally prefer Seed and Series A opportunities for new investments.

While the firm is agnostic to sector and indication, the firm does have several areas of particularly high interest. Currently, the firm is interested in nucleic acid-based technologies and therapeutics, manufacturing and automation tools, and discovery tools. While the firm is open to any indication, the firm does prefer to invest in less crowded disease areas.

The firm places a strong emphasis on the team when investing.
 
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

The corporate venture arm of a senior living community invests strategically in companies that can enhance their services or the elderly population quality of life in general, including in healthcare. Within healthcare, the firm is willing to invest in digital health, medical devices and diagnostic/monitoring technologies, but will not invest in therapeutics. The firm generally invests in seed to series A, and will occasionally act as a company builder, co-founding a company around a promising technology. In an initial investment, the firm will generally invest no more than $.5M, but has the ability to invest in follow-on rounds. As a strategic investor, in addition to capital, the firm can employ their facilities for pilot programs, and will occasionally do so before investing. The firm is primarily interested in Israeli companies, but will invest globally.

The firm invests in multiple sectors related to the elderly population quality of life. These technologies can include medical devices, diagnostics and digital health technologies. Examples include chronic disease management software or monitoring devices.

The firm invests in multiple sectors related to the elderly population quality of life. These technologies can include medical devices, diagnostics and digital health technologies. Examples include chronic disease management software or monitoring devices.
 
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

The holding company of a large corporation is dedicated to fostering innovation across by investing in and partnering with strategic startups. The corporate venture capital arm is open to global opportunities and is geography and stage agnostic, but has specific preferences depending on the technology sector.

Healthcare/Medical is one of the major focus areas of the firm. The corporate venture capital arm is interested therapeutics solutions such as solutions beyond the pill (digital therapeutics) and around the pill (delivery systems etc). Therapeutics areas of interest are CNS, Autoimmune diseases, metabolic diseases, regenerative medicine, Aging related solutions and Vaccines. The corporate venture capital arm is also interested in diagnostics solutions based on genomics, metagenomics, metabolomics, healthcare ICT (biosensors etc), and medical big data. Furthermore, medical devices for wound care, bone cement and hospital related infection treatment is also is an area of interest and is open to all classes of medical devices including 510k and PMA.

The corporate venture capital arm has a close, collaborative relationship with other business branches within the corporation, and can also present opportunities to the pharma branch, CRO, CDMO branches as appropriate.

The firm is a flexible investor and does not require companies to have a Japan-centric angle. For medical device & digital therapeutics opportunities, the group does prefer technologies with strong promise in the US market. The venture group has a close relationship with all other business operations within the corporation and can actively support companies by leveraging these relationships.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.